ANKRD42

Across TCGA pan-cancer cohorts, ANKRD42 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD42 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ANKRD42 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD42 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and BLCA are the cancer types where ANKRD42 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.112	0.578	.002	24	view →
UCEC	DFS	Median	All	0.966	0.625	.013	24	view →
BLCA	DFS	Median	III,IV	0.235	0.575	.032	9	view →
READ	DFS	Median	All	0.111	0.799	.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKRD42–BRCA (OS)

Open the BRCA breakdown →